Industry Focus

Biogen's shares fell 30% because it's bailing on a once-promising Alzheimer's disease drug, but it might not be a bargain worth buying yet. Also, why a shareholder revolt could cause Bristol-Myers and Celgene's merger to fall apart.

Check out more of our content here:

Direct download: 20190327_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT